Reuters News

Third vaccine dose boosts protection against Delta variant – Pfizer

Pfizer on Wednesday (July 28) raised its full-year sales forecast for the COVID-19 vaccine it developed with Germany’s BioNTech by 29% to $33.5 billion, as nations stock up on doses for the rest of the year.

The company also said it could apply for an emergency use authorization for a potential booster dose as early as August, reiterating that a third shot will likely be needed to enhance protection amid a resurgence in infections in many countries.

New early data showed that a third dose generated virus-neutralizing antibodies more than 5 times higher in younger people and more than 11 times higher in older people than from two doses, Pfizer said.

Pfizer shares were up 2% at $42.98 in morning trading.

The text, photographs, video, graphics, metadata, quotes, data, information, and all protectable intellectual property available through the this website is the property of Reuters and its licensors. It is provided by Reuters and its licensors to you for your personal use and information only. You may not use the Content or Service for any commercial purpose. You acknowledge that by accessing and using this the service, you agree to be legally bound by and hereby consent to these terms of use and the privacy policy.  Learn more in https://www.reutersagency.com/en/about/brand-attribution-guidelines/

Tags:
Content Types: TextVideo
Topics: Health
Platforms: Reuters ConnectReuters.com PlatformWorld News Express
Regions & Locations: Americas
Media Types: TextVideo
Sign up for email updates

Subscribe
Sign up for email updates